Project Grant R21AI185365
Award Date
6/21/24
Completion Date
4/30/26
Dollars Obligated
$883K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Pittsburgh, PA 15222, USA
Similar Awards
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $152,216 to the University of Pittsburgh to conduct research on anti-fungal immune responses in the female reproductive tract. The research aims to determine the cellular and molecular basis for how type 3 cytokine signaling orchestrates immune control of vulvovaginal candidiasis (VVC), a prevalent and...
This federal Project Grant award of $318,554.00 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) will support research at Valparaiso University to investigate the regulation of chloride-driven fluid secretion and its subversion by the fungal pathogen Candida albicans. The key objectives of this 3-year research project are to: 1) determine the role of the hormone 17-β...
This $857,215 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to investigate how the fungal pathogen Candida albicans adapts and causes disease in different host environments. The research aims to decipher how the fungal protein acetylation regulator GCN5 mediates niche-specific virulence of C. albicans in mouse models of oropharyngeal and invasive candidiasis. By...
This $300,000 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under CFDA 93.855 Allergy and Infectious Diseases Research program aims to develop an anti-Candida peptide vaccine. The goal is to create a vaccine that can be used alone or as an adjunct to antifungal drugs to reduce fungal burden and morbidity due to life-threatening disseminated candidiasis, a common bloodstream infection in hospitalized patients. The project will utilize a novel...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $745,752 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Mayo Clinic. The funding supports research to develop an HIV-1 vaccine that can generate strong immune responses at mucosal surfaces, the primary sites of HIV exposure. Key aspects of the project include: Evaluating the ability of a "single-cycle" adenovirus (SC-AD) vaccine platform to amplify antigen production...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $494,696 to support research on the translational control of host environmental stress responses in the fungal pathogen Candida albicans. The research aims to determine how the key regulatory proteins ASC1 and EIF4E-BPs function together to translationally control C. albicans morphology, stress responses, and virulence...
This Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), provides $473,632 to the University of Toledo to investigate the role of megakaryocytes (MEGs) in oral and craniofacial immune responses during oropharyngeal candidiasis (OPC) caused by Candida albicans. The central hypothesis is that interleukin-17 receptor (IL-17R) signaling in MEGs is critical for mediating protection against...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $251,250 to The University of Texas MD Anderson Cancer Center to develop CAR-T cell and CAR-macrophage based cell therapies to target and recruit the host immune system to protect against systemic Candida infections. The primary objectives are to generate CAR constructs by fusing Candida-specific targeting domains with...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $258,990.00 to Boston Children's Hospital to examine the role of the Candida albicans TOR1 kinase and its N-terminal heat repeats in enabling the fungal pathogen to withstand oxidative stress from the host immune system. The research aims to define the interactions between TOR1 and its N-terminal heat repeats...
The University of Southern California (USC) received a $623,986 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research (CFDA 93.855) program. The funding supports a research project to study the genetic and molecular mechanisms that enable fungi, specifically the opportunistic pathogen Saccharomyces cerevisiae, to persist and cause infections in mammalian hosts. Key objectives include: Identifying causal...